NIAID Banner Logo Image

HIV Citation List: MaY 13 - May 26, 2009

Pubmed citations:

1. [CCR5 Antagonists: a New Class of Antiretrovirals.] Peytavin G, Calvez V, Katlama C. Therapie. 2009 Jan-Feb;64(1):9-16. Epub 2009 May 26. French. PMID: 19463248

2. The Novel CXCR4 Antagonist, KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100. Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, Okuma K, Huang W, Toma J, Komano J, Yanaka M, Tanaka Y, Yamamoto N. Antimicrob Agents Chemother. 2009 May 18. [Epub ahead of print] PMID: 19451305

3. On the inhibition of HIV-1 protease by hydrazino-ureas displaying the N-->C=O interaction. Waibel M, Pitrat D, Hasserodt J. Bioorg Med Chem. 2009 May 15;17(10):3671-9. Epub 2009 Apr 5. PMID: 19394228

4. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. Sayer JM, Louis JM. Proteins. 2009 May 15;75(3):556-68. PMID: 1895141

5. Pharmacovirological Impact of an Integrase Inhibitor on HIV-1 cDNA Species in vivo. Goffinet C, Allespach I, Oberbremer L, Golden PL, Foster SA, Johns BA, Weatherhead JG, Novick SJ, Chiswell KE, Garvey EP, Keppler OT. J Virol. 2009 May 20. [Epub ahead of print] PMID: 19458008

6. Circular CCR5 peptide conjugates and uses thereof (WO2008074895). Sommerfelt MA. Expert Opin Ther Pat. 2009 May 21. [Epub ahead of print] PMID: 19456281

7. The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Hauber I, Hohenberg H, Holstermann B, Hunstein W, Hauber J. Proc Natl Acad Sci U S A. 2009 May 18. [Epub ahead of print] PMID: 19451623

8. Biological and physical characterization of the X4 HIV-1 suppressive factor secreted by LPS-stimulated human macrophages. Mikulak J, Gianolini M, Versmisse P, Pancino G, Lusso P, Verani A. Virology. 2009 May 15. [Epub ahead of print] PMID: 19447459

9. Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D. Pharmacol Ther. 2009 May 14. [Epub ahead of print] PMID: 19447134

10. Doubly Loaded cycloSaligenyl-Pronucleotides - 5,5'-Bis-(cycloSaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine Monophosphates). Gisch N, Balzarini J, Meier C. J Med Chem. 2009 May 13. [Epub ahead of print] PMID: 19438207

11. Synthetic Peptides of Hepatitis G Virus (GBV-C/HGV) in the Selection of Putative Peptide Inhibitors of the HIV-1 Fusion Peptide. Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I. J Phys Chem B. 2009 May 21;113(20):7383-91. PMID: 19402654


ISI Web of Science citations:

12. Anti HIV-1 Agents 2. Discovery of Dibenzofurans as New HIV-1 Inhibitors In Vitro. Fan, LL; Liu, WQ; Xu, H; Yang, LM; Lv, M; Zheng, YT. LETTERS IN DRUG DESIGN & DISCOVERY, 2009; 6(3): 178-180.

13. Development and Characterization of Peptidic Fusion Inhibitors Derived HIV-1 gp41 with Partial D-Amino Acid Substitutions. Gaston, F; Granados, GC; Madurga, S; Rabanal, F; Lakhdar-Ghazal, F; Giralt, E; Bahraoui, E. CHEMMEDCHEM, 2009; 4(4): 570-581.

14. 2 '-Deoxy-nucleoside Analogs can be Potent Dual Inhibitors of HCV and HIV Replication with Selectivity against Human Polymerases. Klumpp, K; Su, GP; Leveque, V; Deval, J; Heilek, G; Rajyaguru, S; Li, Y; Hang, JQ; Ma, H; Inocencio, N; Kalayanov, G; Winqvist, A; Smith, DB; Cammack, N; Johansson, NG; Najera, I. ANTIVIRAL RESEARCH, 2009; 82(2): A19.

15. Feglymycin, a Unique 13 Amino-acid Peptide, With a Novel Mechanism of Anti-HIV-1 Activity. Schols, D; Ferir, G; Hoorelbeke, B; Hanchen, A; Dettner, F; Sussmuth, RD. ANTIVIRAL RESEARCH, 2009; 82(2): A25.

16. Immediate and Persistent Anti-HIV-1 Activity of the Biguanide-based Compound NB325 Involves Specific Interactions with the Viral Co-receptor CXCR4. Thakkar, N; Pirrone, V; Passic, S; Labib, M; Rando, R; Wigdahl, B; Krebs, F. ANTIVIRAL RESEARCH, 2009: 82(2): A26.

17. From beta-Amino-gamma-Sultone to New Bicyclic Pyridine and Pyrazine Heterocyclic Systems: Discovery of a Novel Class of HIV-1 Non-nucleoside Inhibitors. Velazquez, S; Castro, S; Balzarini, J; Camarasa, MJ. ANTIVIRAL RESEARCH, 2009; 82(2): A26-A27.

18. A Small Llama Antibody Fragment Efficiently Inhibits the HIV Rev Multimerization In Vitro. Vercruysse, T; Pardon, E; Steyaert, J; Daelemans, D. ANTIVIRAL RESEARCH, 2009; 82(2): A27.

19. Indole Derivatives Are Potent Inhibitors of HIV Integrase.Selvam, P; Maddali, K; Pommier, Y. ANTIVIRAL RESEARCH, 2009: 82(2): A42.

20. Highly Potent and Dual-acting Pyrimidinedione Inhibitors of HIV-1 Possess a High Genetic Barrier to Resistance. Liu, XY; Zhan, P; Pannecouque, C; De Clercq, E. ANTIVIRAL RESEARCH, 2009: 82(2): A44.

21. Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides as Potent NNRTIS. Liu, XY; Zhan, P; Pannecouque, C; De Clercq, E. ANTIVIRAL RESEARCH, 2009: 82(2): A44-A45.

22. CXCR4 Chemokine Receptor Antagonists from Ultra-rigid Metal Complexes Profoundly Inhibit HIV-1 Replication, and also AMD3100-resistant Strains. Archibald, SJ; Daelemans, D; Hubin, TJ; Huskens, D; Schols, D; Van Laethem, K; De Clercq, E; Pannecouque, C. ANTIVIRAL RESEARCH, 2009: 82(2): A45.

23. Synthesis and Evaluation of Novel Acyclovir Phosphoramidates as Anti-HIV Agents. Carta, D; McGuigan, C; Margolis, L; Balzarini, J. ANTIVIRAL RESEARCH, 2009: 82(2): A56.

24. Design, Synthesis and SAR of New Potent HIV-1 RT Inhibitors. Chimirri, A; De Clercq, E; Maga, G; Logoteta, P; Ferro, S; De Luca, L; Iraci, N; Pannecouque, C; Monforte, A. ANTIVIRAL RESEARCH, 2009: 82(2): A56-A57.

25. The Application of Phosphoramidate Protide Technology to Acyclovir confers Novel Anti-HIV Inhibition. Derudas, M; McGuigan, C; Brancale, A; Margolis, L; Balzarini, J. ANTIVIRAL RESEARCH, 2009: 82(2): A57.

26. 4,4-Disubstituted Cyclohexylamine based CCR5 Chemokine Receptor Antagonists as Anti-HIV-1 agents. Duan, MS; Kazmierski, W; Aquino, C; Ferris, R; Kenakin, T; Watson, C; Wheelan, P. ANTIVIRAL RESEARCH, 2009: 82(2): A57.

27. The Development of HIV-1 NCP7 Inhibitors as Components in Combination Topical Microbicides. Watson, K; Powers, K; Yang, L; Hartman, T; Buckheit, R. ANTIVIRAL RESEARCH, 2009: 82(2): A66-A67.

28. The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy
Harris, K; Sergueev, D; Reno, J. RETROVIROLOGY, 2006; 3: S13.

29. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis .Harris, KS; Brabant, W; Styrchak, S. ANTIVIRAL RESEARCH, 2005; 67(1): 1-9.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: September 2023